Laboratory Corporation of America® Holdings Successfully Completes Acquisition of Sequenom, Inc.
07 Setembro 2016 - 9:58AM
Business Wire
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:
LH) today announced the successful completion of the offering
period for the cash tender offer by its direct wholly owned
subsidiary, Savoy Acquisition Corp. (Purchaser), for all
outstanding shares of common stock of Sequenom, Inc. (NASDAQ: SQNM)
(Sequenom), including the associated preferred stock purchase
rights (together with the common stock, the Shares). The depositary
for the tender offer has advised LabCorp that, as of 12:01 a.m.,
Eastern time, on September 7, 2016, the expiration of the offering
period, stockholders of Sequenom had validly tendered 82,901,857
Shares (including Shares tendered through notices of guaranteed
delivery) during the offering period, representing an aggregate of
approximately 69% of Sequenom’s outstanding shares of common stock
as of such time (or approximately 67% of outstanding shares
excluding notices of guaranteed delivery), which Shares are
sufficient to have met the minimum condition of the offer and to
enable the Merger (as defined below) to occur under Delaware law
without a vote of Sequenom’s stockholders. Purchaser has accepted
for payment all Shares validly tendered and not properly withdrawn
during the offering period, and the consideration for all such
Shares either has been paid or will be paid promptly. The
acceptance of the Shares effective as of September 7, 2016
constitutes a “Fundamental Change” and a “Make-Whole Fundamental
Change” under the indentures related to Sequenom’s 5.00%
convertible senior notes due 2017 and the Sequenom’s 5.00%
convertible exchange senior notes due 2018.
“With the addition of Sequenom, LabCorp is a market leader for
non-invasive prenatal testing, women’s health and reproductive
genetics,” said David P. King, chairman and chief executive officer
of LabCorp. “This strategic acquisition also expands our reach both
domestically and internationally and furthers our mission to
improve health and improve lives around the globe.”
LabCorp also announced that, following the completion of the
offering period, Purchaser was merged with and into Sequenom (the
Merger) without a vote of the stockholders of Sequenom, as
permitted by the Delaware General Corporation Law. In the Merger,
each Share not tendered and accepted for payment in the offer,
other than those Shares with respect to which the holders properly
exercise appraisal rights and Shares held by LabCorp or Purchaser,
has been converted into the right to receive $2.40 net to the
seller in cash, without interest thereon and subject to applicable
withholding taxes. As a result of the Merger, Sequenom became a
direct wholly owned subsidiary of LabCorp and Sequenom’s shares
will cease to be traded on the NASDAQ Global Select Market.
About LabCorp®
Laboratory Corporation of America® Holdings (NYSE: LH), an
S&P 500 company, is the world’s leading healthcare diagnostics
company, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostic solutions,
brings innovative medicines to patients faster and develops
technology-enabled solutions to change the way care is provided.
With net revenue in excess of $8.5 billion in 2015, LabCorp’s
50,000 employees serve clients in 60 countries. To learn more about
LabCorp visit www.labcorp.com and to learn more about Covance Drug
Development visit www.covance.com.
This press release contains forward-looking statements including
with respect to the successful acquisition of Sequenom by LabCorp,
the payment of consideration for Sequenom shares tendered in the
Offer and the cessation of trading of Sequenom’s shares on the
NASDAQ Global Select Market. These statements are subject to risks
and uncertainties that could cause actual results to differ
materially from those suggested by these forward-looking
statements. Risks and uncertainties include, among others, the
successful integration of Sequenom into LabCorp’s business
subsequent to the closing of the transaction; adverse reactions to
the proposed transaction by customers, suppliers or strategic
partners; dependence on key personnel and customers; reliance on
proprietary technology; management of growth and organizational
change; risks associated with litigation; competitive actions in
the marketplace and adverse actions of governmental and other
third-party payers; as well as other factors detailed in LabCorp’s
and Sequenom’s filings with the SEC including LabCorp’s Annual
Report on Form 10-K for the year ended December 31, 2015, and
subsequent SEC filings, and Sequenom’s Annual Report on Form 10-K
for the year ended December 31, 2015, and subsequent SEC filings.
LabCorp undertakes no obligation to update these statements as a
result of new events, circumstances or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160907006040/en/
Laboratory Corporation of America® HoldingsInvestors:Paul
Surdez, 336-436-5076Investor@labcorp.comorMedia:Pattie Kushner,
336-436-8263Media@labcorp.com
Sequenom, Inc. (NASDAQ:SQNM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Sequenom, Inc. (NASDAQ:SQNM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024